Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Evaluating Retinal Sensitivity Losses on Microperimetry in Diabetic Macular Ischemia – One Year Result
Author Affiliations & Notes
  • Wei-Shan Tsai
    Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Sridevi Thottarath
    Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Sarega Gurudas
    Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Liz Pearce
    Boehringer Ingelheim International GmbH, Ingelheim, Rheinland-Pfalz, Germany
  • Andrea Giani
    Boehringer Ingelheim International GmbH, Ingelheim, Rheinland-Pfalz, Germany
  • Taffeta Yamaguchi
    Boehringer Ingelheim International GmbH, Ingelheim, Rheinland-Pfalz, Germany
  • Jinzhi Zhao
    Singapore National Eye Centre, Singapore, Singapore, Singapore
  • Gemmy Cheung
    Singapore National Eye Centre, Singapore, Singapore, Singapore
  • Sobha Sivaprasad
    Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • Footnotes
    Commercial Relationships   Wei-Shan Tsai None; Sridevi Thottarath None; Sarega Gurudas None; Liz Pearce Boehringer Ingelheim, Code E (Employment); Andrea Giani Boehringer Ingelheim, Code E (Employment); Taffeta Yamaguchi Boehringer Ingelheim, Code E (Employment); Jinzhi Zhao None; Gemmy Cheung Boehringer Ingelheim, Code F (Financial Support); Sobha Sivaprasad Boehringer Ingelheim, AbbVie, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, Novartis, Eyebiotech, Eyepoint Phamaceuticals, Janssen Pharmaceuticals, Nova Nordisk, Optos, Ocular Therapeutix, Kriya Therapeutics, OcuTerra, Roche, Stealth Biotherapeutics. Sanofi., Code F (Financial Support)
  • Footnotes
    Support  SIVS1048 – Investigator-initiated study funded by Boehringer Ingelheim. The research was supported by NIHR Moorfields Clinical Research Facility and Biomedical Research Centre.
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 6350. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Wei-Shan Tsai, Sridevi Thottarath, Sarega Gurudas, Liz Pearce, Andrea Giani, Taffeta Yamaguchi, Jinzhi Zhao, Gemmy Cheung, Sobha Sivaprasad; Evaluating Retinal Sensitivity Losses on Microperimetry in Diabetic Macular Ischemia – One Year Result. Invest. Ophthalmol. Vis. Sci. 2024;65(7):6350.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report microperimetry changes over one year in diabetic macular ischemia (DMI), defined as optical coherence tomography-angiography (OCT-A) confirmed foveal avascular zone (FAZ) ≥0.5 mm2 or parafoveal capillary dropout ≥1 quadrant.

Methods : This one-year prospective observational study was conducted at two tertiary centers. Eighty-eight stable-treated proliferative diabetic retinopathy patients (97 eyes) with evidence of DMI and best-corrected visual acuity ≥54 Early Treatment Diabetic Retinopathy Study letters (Snellen equivalent 20/80) were recruited. Microperimetry was done to assess the mean change in overall retinal sensitivity (oRS) and point-wise sensitivity (PWS) at baseline and twelve months within the 3x3 millimeter (mm) macula. Decreased retinal sensitivity (RS) was defined as <25 decibels (dB). Severe and mild RS losses were defined as 7 and 2 dB losses in PWS, respectively. The areas most vulnerable to RS loss were explored.

Results : There was no statistically significant change from baseline in mean oRS at one year. Only 1% had severe oRS loss of ≥7 dB, and 4% lost ≥7 dB in ≥5 loci, while 10% showed mild oRS of ≥2 dB, and 73% lost ≥2 dB in ≥5 loci. The locations most vulnerable to severe RS loss were the foveola and temporal parafovea (Figure 1). Eyes with baseline oRS ≥25 dB were more likely to experience oRS loss in the 3x3 mm macular region (55% vs 32%, P = .01) and superior parafovea (53% vs 28%, P = .01) (Table 1).

Conclusions : Severe oRS loss of ≥7 dB over one year in eyes with DMI is relatively uncommon compared to mild oRS loss of ≥2 dB. Severe PWS losses were mainly observed in the foveola and temporal parafoveal areas.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

Figure 1. A Heat Map of the Most Vulnerable Loci at Risks of Severe and Mild Retinal Sensitivity Loss at One Year. The most vulnerable regions to severe retinal sensitivity loss are the foveola and temporal parafovea (highlighted in red on the loss ≥7 dB map).

Figure 1. A Heat Map of the Most Vulnerable Loci at Risks of Severe and Mild Retinal Sensitivity Loss at One Year. The most vulnerable regions to severe retinal sensitivity loss are the foveola and temporal parafovea (highlighted in red on the loss ≥7 dB map).

 

Table 1. A Comparison of Retinal Sensitivity Loss at One Year Between Eyes with Good and Impaired Retinal Sensitivity at Baseline Using 25 dB as the Cutoff. Eyes with oRS ≥25 dB were more likely to have RS loss of any degree in the 3x3 macular region and superior parafovea than their counterparts.

Table 1. A Comparison of Retinal Sensitivity Loss at One Year Between Eyes with Good and Impaired Retinal Sensitivity at Baseline Using 25 dB as the Cutoff. Eyes with oRS ≥25 dB were more likely to have RS loss of any degree in the 3x3 macular region and superior parafovea than their counterparts.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×